Evidence map›Paper›PMID 31842381›Full record

ArticleJournal of clinical medicine2019

Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408.

Koichi Takayama, Junji Uchino, Masaki Fujita, Shoji Tokunaga, Tomotoshi Imanaga, Ryotaro Morinaga, Noriyuki Ebi, Sho Saeki, Kazuya Matsukizono, Hiroshi Wataya and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Koichi TakayamaResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8190395, Japan.
Junji UchinoDepartment of Respiratory Medicine, Kyoto Prefectural University of Medicine, Kyoto 6020841, Japan.ORCID 0000-0003-0651-7767
Masaki FujitaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka 8140133, Japan.
Shoji TokunagaMedical Information Center, Kyushu University Hospital, Fukuoka 8190395, Japan.
Tomotoshi ImanagaDepartment of respiratory disease, Nippon Steel Yawata Memorial Hospital, Kitakyushu 8058508, Japan.
Ryotaro MorinagaDepartment of Medical Oncology, Oita University Faculty of Medicine, Yuhu 8795593, Japan.
Noriyuki EbiDepartment of Respiratory Medicine, Iizuka Hospital, Iizuka, 8208505 Japan.
Sho SaekiDepartment of Respiratory Medicine, Kumamoto University Hospital, Kumamoto 8608556, Japan.
Kazuya MatsukizonoDepartment of Internal Medicine, Kagoshima City Hospital, Kagoshima 8908544, Japan.
Hiroshi WatayaDepartment of Internal Medicine, Saiseikai Fukuoka General Hospital, Fukuoka 8100001, Japan.
Tadaaki YamadaDepartment of Respiratory Medicine, Kyoto Prefectural University of Medicine, Kyoto 6020841, Japan.ORCID 0000-0002-6945-281X
Yoichi NakanishiResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8190395, Japan.ORCID 0000-0001-7813-3469
Kyoto Prefectural University of Medicine · JPKyushu University · JPAso Iizuka Hospital · JPFukuoka University Hospital · JPKagoshima City Hospital · JPKumamoto University Hospital · JPKyushu University Hospital · JPNippon Steel Yawata Memorial Hospital · JPOita University · JPSaiseikai Fukuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs docetaxel plus S-1 may be feasible for cancer treatment, we conducted a phase I/II trial to determine the recommended docetaxel dose and the fixed S-1 dose (phase I), as well as confirm the regimen's efficacy and safety (phase II) for previously-treated patients with advanced non-small cell lung cancer.

methodsPatients ≤75 years with performance status ≤1 and adequate organ function were treated at three-week intervals with docetaxel on day 1 and 80 mg/m

resultsThe recommended doses were 50 mg/m

conclusionFifty mg/m

Indexed as

chemotherapydocetaxelnon-small cell lung cancerphase I/II trialpreviously treated patientsS-1

Identifiers

PMID31842381
PMCPMC6947543
OpenAlexW2996211065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.